YILIMART - hCMV-pp65 Antigen Delivery Reagent

The hCMV-pp65 Antigen Delivery Reagent has been developed for specific targeting of pp65 CMV antigen to antigen uptake receptors on human APCs. Such targeted delivery of antigen allows the analysis of antigen uptake, processing, and antigen presenting capability of targeted APCs.

Background information

The reagent consists of pp65 peptides covalently coupled to a dendrimer and a monoclonal, anti-biotin-FITC conjugate. Using a biotinylated primary antibody, the antigen can be specifically targeted to any surface molecule of the relevant APCs. This allows the identification and functional characterization of antigen uptake receptors, as well as research on vaccine strategies.

^1-3

Downstream applications

The hCMV-pp65 Antigen Delivery Reagent is well suited for analysis of

antigen uptake by antigen-presenting cells, i.e., DCs, macrophages, and B cells.
antigen processing and intracellular trafficking of endocytotic receptors.
cross presentation of antigens. protocols for antigen delivery for DC vaccination.

Selected references
1. Bonifaz, L. et al. (2002)
  
  Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8
  ⁺
  T cell tolerance.
  
  J. Exp. Med. 196: 1627-1638
2. Dudziak, D. et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111
3. Caminschi, I. et al. (2008) The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273

查看数据文件查看下载

hCMV-pp65 Antigen Delivery Reagent

For research use only

您浏览过的商品

Background information

Downstream applications

Selected references

相关产品